
Gefitinib improved progression-free survival and some quality of life measures when used as second-line therapy for esophageal cancer.

Gefitinib improved progression-free survival and some quality of life measures when used as second-line therapy for esophageal cancer.

Coverage from the 2012 European Society for Medical Oncology congress, held at the Austria Center Vienna from September 28 - October 2, in Vienna, Austria.